Atigotatug/Nivolumab

N/A

Report date: 2025/01/17 10:36:11

Base Information

Drug NameAtigotatug/Nivolumab
Drug Alias NameNivolumab/BMS-986012BMS-986012+NivolumabBMS-986489
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionProgrammed cell death protein 1 inhibitorsGanglioside fucosyl GM1 inhibitors
TargetsProgrammed cell death protein 1Ganglioside fucosyl GM1
Therapy Area/IndicationsSmall Cell Lung Carcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[26] 
CombinationsYes NivolumabAtigotatug
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesBristol Myers Squibb SrlcompanyBristol-Myers Squibb (China) Investment Co LtdBristol-Myers Squibb Company +[4] 
Inactive CompaniesN/A
Active IndicationsSmall Cell Lung Carcinoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A